ClinicaliQ Trial Snapshot
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) — Recruiting • Phase III • Oncology • NCT07318558.
- What is being tested: Sacituzumab govitecan-hziyah (Sac-TMT), an antibody-drug conjugate targeting TROP-2, is being evaluated as a treatment option for advanced ovarian cancer patients who are homologous recombination deficiency (HRD) negative and have limited alternative therapeutic options.
- Patient eligibility overview: The trial includes adults with advanced ovarian cancer who are HRD-negative (ineligible for PARP inhibitors), have progressed after platinum-based chemotherapy, and have exhausted or are ineligible for standard treatment options; prior treatment history and performance status determine specific inclusion….
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to…
Eligibility Snapshot
- The main inclusion criteria include but are not limited to the following: * Has histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of certain histologies. * Has completed primary debulking surgery or interval debulking surgery. * Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol. * Has provided tumor tissue that is not previously irradiated. * If human immunodeficiency virus (HIV) infected, has well-controlled HIV on antiretroviral therapy. * Has undetectable hepatitis B virus (HBV) viral load and received HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive. * Has undetectable hepatitis C virus (HCV) viral load if has a history of HCV infection. The main
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.